- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Grapevine Today
By the People, for the People
Alpha Cognition Receives U.S. Patent for Brain Injury Treatment
The new ALPHA-1062 drug aims to help patients recover from traumatic brain injuries.
Apr. 1, 2026 at 10:07pm
Got story updates? Submit your updates here. ›
Alpha Cognition, a biopharmaceutical company, has received a U.S. patent for its ALPHA-1062 drug, which is designed to treat traumatic brain injuries. The company is headquartered in Vancouver, British Columbia, with additional operations in Grapevine, Texas.
Why it matters
Traumatic brain injuries can have devastating long-term effects, so new treatments that can help patients recover are significant advancements in the field of neurological care. Alpha Cognition's patented drug represents a potential breakthrough in addressing this serious medical issue.
The details
ALPHA-1062 is a new drug developed by Alpha Cognition that aims to aid in the recovery of patients who have suffered traumatic brain injuries. The company has now received a U.S. patent for the drug, which marks an important milestone in bringing this potential treatment to market.
- Alpha Cognition received the U.S. patent for ALPHA-1062 on April 1, 2026.
The players
Alpha Cognition
A biopharmaceutical company that develops treatments for neurological conditions, including traumatic brain injuries.
What’s next
Alpha Cognition plans to continue clinical trials and the regulatory approval process for ALPHA-1062 in order to bring the drug to market as a treatment for traumatic brain injuries.
The takeaway
The patenting of ALPHA-1062 represents an important step forward in addressing the significant medical need for new therapies that can help patients recover from the debilitating effects of traumatic brain injuries.
